Fundraising FoxStimuSIL
Wilmington, US · Founded 2021 · Delaware corporation · 1 known investors
Find your way into StimuSIL
Sign up to see every warm intro you have to StimuSIL
- Paths you didn't know you had: your email and LinkedIn already hold routes to the StimuSIL team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
StimuSIL is a medical device company developing subdermal photobiomodulation technology that uses patented methods to deliver light-based stimulation beneath the skin's melanin layer for dermatology and aesthetics indications. Its lead preclinical candidate targets androgenetic alopecia (hair loss), with a research pipeline covering vitiligo, psoriasis, wrinkles, cellulite, and acne scars.
Founders & leadership
StimuSIL was founded in 2021 by Ana Isabel Villalba Villar and Ana Villalba.
AI
Ana Isabel Villalba VillarFounderAna Isabel Villalba Villar is an engineer with expertise in product design and data analysis, and founder of StimuSIL, a medical device company developing subdermal photobiomodulation technology for dermatology and aesthetics.
AV
Ana VillalbaFounder & Chief Executive OfficerAna Villalba is an engineer with background in product design and data analysis who founded StimuSIL, a medical device company developing subdermal photobiomodulation technology for dermatology and aesthetic applications.
AV
Ana Villalba VillarNamed on SEC filing
PV
Pablo VillalbaFounder & ChairmanHe previously founded and led 8fit, a fitness and nutrition app, and Redbooth, a collaboration software company, after co-founding the online course venture Teras-LMA and working as an engineer at Traten Energy.
FY
Firat YerlikayaNamed on SEC filing
Board
AG
Abidin GulmusBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.3M disclosed across 4 rounds · 2022–2024
▶$600KraisedMar 2025 · 2 investors · BiotechnologyRule 506(b)
▶$600KraisedMar 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Abidin GulmusDirector
- Ana Villalba VillarExecutive Officer, Director
- Pablo VillalbaExecutive Officer, Director
- Offering amount
- $600K
- Amount sold
- $600K
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.1MraisedMay 2024 · 7 investors · BiotechnologyRule 506(b)
▶$1.1MraisedMay 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Firat YerlikayaDirector
- Pablo VillalbaExecutive Officer, Director
- Ana Villalba VillarExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$48.8KraisedSep 2023 · 1 investors · BiotechnologyRule 506(b)
▶$48.8KraisedSep 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pablo VillalbaExecutive Officer, Director
- Firat YerlikayaDirector
- Ana Villalba VillarExecutive Officer, Director
- Offering amount
- $48.8K
- Amount sold
- $48.8K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$575KraisedAug 2022 · 12 investors · BiotechnologyRule 506(b)
▶$575KraisedAug 2022 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pablo VillalbaExecutive Officer, Director
- Ana Villalba VillarExecutive Officer, Director
- Firat YerlikayaDirector
- Offering amount
- $575K
- Amount sold
- $575K
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does StimuSIL do?
- StimuSIL is a medical device company developing subdermal photobiomodulation technology that uses patented methods to deliver light-based stimulation beneath the skin's melanin layer for dermatology and aesthetics indications. Its lead preclinical candidate targets androgenetic alopecia (hair loss), with a research pipeline covering vitiligo, psoriasis, wrinkles, cellulite, and acne scars.
- Who founded StimuSIL?
- StimuSIL was founded by Ana Isabel Villalba Villar, Ana Villalba in 2021.
- Who are StimuSIL's investors?
- StimuSIL's investors include Capital Cell.
- How much funding has StimuSIL raised?
- StimuSIL has disclosed $2.3M raised across 4 rounds.
- Where is StimuSIL headquartered?
- StimuSIL is headquartered in Wilmington, US.